S&P/ASX 300 Index (ASX: XKO) stock Nanosonics Ltd (ASX: NAN) is enjoying a strong run today.
Shares in the Aussie infection prevention company closed yesterday trading for $3.89. In morning trade on Wednesday, shares jumped to $4.35 apiece, up 11.8%. After some likely profit-taking, at the time of writing, Nanosonics shares are trading for $4.02 apiece, up 3.3%.
For some context, the ASX 300 is up 0.5% at this same time.
Here's why the ASX 300 stock is grabbing investor attention today.
ASX 300 stock lifts off on FDA news
The big news out today involves Nanosonics' trophon technology, which provides high-level disinfection against a broad range of potentially harmful organisms in clinical environments.
In an announcement this morning, Nanosonics reported that it had received clearance from the US Food and Drug Administration (FDA) for its latest trophon innovation. This now enables the ASX 300 stock to commercially launch trophon3 and trophon2 Plus in the world's top economy.
Trophon2 is a software upgrade package for existing trophon2 users, allowing them to access the new features available with trophon3. Noting that there are approximately 20,000 trophon2 devices globally, management said the new package represents a significant software upgrade opportunity.
According to the release, trophon3 delivers a range of new benefits while maintaining "the highest standard in clinical efficacy" for patient safety.
The company said:
Fully programmable and adaptable, trophon3 can be customised to suit a range of customer workflows enhancing efficiency while delivering consistent, reliable disinfection in a safe, effective, and environmentally friendly way.
It's also more than 40% faster than previous generations, with expanded digital integration capabilities and what the company says is the widest traceability capabilities in the ultrasound reprocessing market.
And trophon3 could help lift the ASX 300 stock longer term.
Management said they expect trophon3 to support continued growth in the company's installed base in both the hospital and private physician market segments. It's also expected to drive a significant upgrade opportunity for approximately 10,000 original trophon EPR devices.
What did management say?
Commenting on the FDA approval sending the ASX 300 stock soaring today, Nanosonics CEO Michael Kavanagh said:
The FDA clearance and USA launch of trophon3 and trophon2 Plus mark important milestones for Nanosonics. These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades.
With today's intraday boost factored in, the Nanosonics share price is up 38% in 2025.
